MOSCOW, Feb. 14, 2022 — The Russian Direct Investment Fund, R-Pharm group and AstraZeneca says results of phase II clinical trials evaluating the safety and immunogenicity of the combined use of AstraZeneca’s vaccine and the first component of the Sputnik V coronavirus vaccine (Sputnik Lite) shows it is safe. The